UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 354

Sortiert nach

Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level

PloS one, 2020-06, Vol.15 (6), p.e0234683-e0234683

2020

Link zum Volltext

Verfügbarkeit prüfen

The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus Monkeys

Molecules (Basel, Switzerland), 2020-03, Vol.25 (6), p.1360

2020

Link zum Volltext

Verfügbarkeit prüfen

Higher doses of naloxone are needed in the synthetic opiod era

Substance abuse treatment, prevention and policy, 2019-02, Vol.14 (1), p.6

2019

Link zum Volltext

Verfügbarkeit prüfen

Brief report: Tempol, a novel antioxidant, inhibits both activated T cell and antigen presenting cell derived cytokines in-vitro from COVID-19 patients

Clinical immunology (Orlando, Fla.), 2021-10, Vol.231, p.108828-108828, Article 108828

2021

Link zum Volltext

Verfügbarkeit prüfen

Human factors study in untrained adolescents comparing a recently approved single-dose epinephrine prefilled syringe with an approved autoinjector

Annals of allergy, asthma, & immunology, 2018-05, Vol.120 (5), p.540-541

2018

Link zum Volltext

Verfügbarkeit prüfen

Human Factors Study of a Newly Approved Epinephrine Prefilled syringe (PFS) for the Emergency Treatment of Allergic Reactions (Type I) including Anaphylaxis

Journal of allergy and clinical immunology, 2018-02, Vol.141 (2), p.AB39-AB39

2018

Link zum Volltext

Verfügbarkeit prüfen

Human factors study of a newly approved prefilled syringe of epinephrine for the treatment of anaphylaxis

Allergy and asthma proceedings, 2018-09, Vol.39 (5), p.389

2018

Link zum Volltext

Verfügbarkeit prüfen

Propofol Phosphate, a Water-Soluble Propofol Prodrug:In Vivo Evaluation

Anesthesia and analgesia, 2002-11, Vol.95 (5), p.1285-1292

2002

Link zum Volltext

Verfügbarkeit prüfen

Higher doses of naloxone are needed in the synthetic opioid era

Substance abuse treatment, prevention and policy, 2019-02, Vol.14 (1), p.1-6, Article 6

2019

Link zum Volltext

Verfügbarkeit prüfen

Strength of conjugate binding to plasmid DNA affects degradation rate and expression level in vivo

Biochimica et biophysica acta, 2000-09, Vol.1523 (1), p.103-110

2000

Link zum Volltext

Verfügbarkeit prüfen

Anti-T-cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma

Journal of allergy and clinical immunology, 2005-12, Vol.116 (6), p.1343-1349

2005

Link zum Volltext

Verfügbarkeit prüfen

Th1/Th2 cells in inflammatory disease states: therapeutic implications

Expert opinion on biological therapy, 2004-12, Vol.4 (12), p.1887-1896

2004

Link zum Volltext

Verfügbarkeit prüfen

Spontaneous and Antigen-Induced Production of HIV-Inhibitory β -Chemokines are Associated with AIDS-Free Status

Proceedings of the National Academy of Sciences - PNAS, 1999-10, Vol.96 (21), p.11986-11991

1999

Link zum Volltext

Verfügbarkeit prüfen

Stabilization of poly- l-lysine/DNA polyplexes for in vivo gene delivery to the liver

Biochimica et biophysica acta, 1999-02, Vol.1444 (2), p.171-190

1999

Link zum Volltext

Verfügbarkeit prüfen

Vaccination against Experimental Allergic Encephalomyelitis with T Cell Receptor Peptides

Science (American Association for the Advancement of Science), 1989-11, Vol.246 (4930), p.668-670

1989

Link zum Volltext

Verfügbarkeit prüfen

Identification of reciprocally regulated gene modules in regenerating dorsal root ganglion neurons and activated peripheral or central nervous system glia

Journal of cellular biochemistry, 2003-04, Vol.88 (5), p.970-985

2003

Link zum Volltext

Verfügbarkeit prüfen

Tumor Cell Surface Expression of Granulocyte-Macrophage Colony-Stimulating Factor Elicits Antitumor Immunity and Protects from Tumor Challenge in the P815 Mouse Mastocytoma Tumor Model

The Journal of immunology (1950), 1999-06, Vol.162 (12), p.7343-7349

1999

Link zum Volltext

Verfügbarkeit prüfen

HIV-specific immunity during structured antiviral drug treatment interruption

Vaccine, 2003-03, Vol.21 (11), p.1066-1071

2003

Link zum Volltext

Verfügbarkeit prüfen

Phenotypic Analysis of Human Immunodeficiency Virus (HIV) Type 1 Cell-Mediated Immune Responses after Treatment with an HIV-1 Immunogen

The Journal of infectious diseases, 1999-09, Vol.180 (3), p.641-648

1999

Link zum Volltext

Verfügbarkeit prüfen

Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV β6 CDR2 peptide

Journal of neuroimmunology, 1997-06, Vol.76 (1), p.29-38

1997

Link zum Volltext

Verfügbarkeit prüfen

Maternal and newborn immunization with a human immunodeficiency virus‐1 immunogen in a rodent model

Immunology, 2002-08, Vol.106 (4), p.549-553

2002

Link zum Volltext

Verfügbarkeit prüfen

Poly-L-lysine-based gene delivery systems. Synthesis, purification, and application

Methods in molecular medicine, 2002, Vol.69, p.1

2002

Link zum Volltext

Verfügbarkeit prüfen

Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations

Journal of neuroimmunology, 1997-06, Vol.76 (1), p.15-28

1997

Link zum Volltext

Verfügbarkeit prüfen

Cell-mediated immune responses to autologous virus in HIV-1-seropositive individuals after treatment with an HIV-1 immunogen

AIDS (London), 2000-11, Vol.14 (16), p.2475-2478

2000

Link zum Volltext

Verfügbarkeit prüfen

HIV-Specific CD4(+) and CD8(+) immune responses are generated with a gp120-depleted, whole-killed HIV-1 immunogen with CpG immunostimulatory sequences of DNA

Journal of interferon & cytokine research, 2000-12, Vol.20 (12), p.1131-1137

2000

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 354

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(323)
Mit Volltextzugriff
(300)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level

The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus Monkeys

Higher doses of naloxone are needed in the synthetic opiod era

Brief report: Tempol, a novel antioxidant, inhibits both activated T cell and antigen presenting cell derived cytokines in-vitro from COVID-19 patients

Human factors study in untrained adolescents comparing a recently approved single-dose epinephrine prefilled syringe with an approved autoinjector

Human Factors Study of a Newly Approved Epinephrine Prefilled syringe (PFS) for the Emergency Treatment of Allergic Reactions (Type I) including Anaphylaxis

Human factors study of a newly approved prefilled syringe of epinephrine for the treatment of anaphylaxis

Propofol Phosphate, a Water-Soluble Propofol Prodrug:In Vivo Evaluation

Higher doses of naloxone are needed in the synthetic opioid era

Strength of conjugate binding to plasmid DNA affects degradation rate and expression level in vivo

Anti-T-cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma

Th1/Th2 cells in inflammatory disease states: therapeutic implications

Spontaneous and Antigen-Induced Production of HIV-Inhibitory β -Chemokines are Associated with AIDS-Free Status

Stabilization of poly- l-lysine/DNA polyplexes for in vivo gene delivery to the liver

Vaccination against Experimental Allergic Encephalomyelitis with T Cell Receptor Peptides

Identification of reciprocally regulated gene modules in regenerating dorsal root ganglion neurons and activated peripheral or central nervous system glia

Tumor Cell Surface Expression of Granulocyte-Macrophage Colony-Stimulating Factor Elicits Antitumor Immunity and Protects from Tumor Challenge in the P815 Mouse Mastocytoma Tumor Model

HIV-specific immunity during structured antiviral drug treatment interruption

Phenotypic Analysis of Human Immunodeficiency Virus (HIV) Type 1 Cell-Mediated Immune Responses after Treatment with an HIV-1 Immunogen

Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV β6 CDR2 peptide

Maternal and newborn immunization with a human immunodeficiency virus‐1 immunogen in a rodent model

Poly-L-lysine-based gene delivery systems. Synthesis, purification, and application

Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations

Cell-mediated immune responses to autologous virus in HIV-1-seropositive individuals after treatment with an HIV-1 immunogen

HIV-Specific CD4(+) and CD8(+) immune responses are generated with a gp120-depleted, whole-killed HIV-1 immunogen with CpG immunostimulatory sequences of DNA

Suchergebnisse filtern